Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is positioned to revolutionize the minimally invasive surgery space with its LIBERTY Endovascular Robotic Surgical System, the only FDA-cleared, single-use, remotely operated robotic system. Its limited market release phase was successful, with rapid customer adoption and shorter sales cycles, and its full market release at the SIR annual scientific meeting this week is expected to drive significant sales ramp-up in the remainder of 2026. Additionally, with a strong IP portfolio, global patent approvals, and a focused go-to-market strategy targeting key procedures and facilities, the company is well-positioned for success.

Bears say

Microbot Medical is a company with limited current sales but high expectations for future growth with its LIBERTY Endovascular Robotic System. However, there are several potential risks that could impede its success, including forecasting, competitive, regulatory, and manufacturing risks. Additionally, the company's current cash balance may not be sufficient to reach profitability in the near term, and its dependence on a single product could also pose a concentration risk.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.